ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer

Colorectal cancer is a highly malignant cancer with poor prognosis and mortality rates. As the first biological agent approved for metastatic colorectal cancer (mCRC), bevacizumab was confirmed to exhibit good performance when combined with chemotherapy and immunotherapy. However, the efficacy of bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Siyuan, Liu, Zaoqu, Xu, Hui, Ge, Xiaoyong, Ren, Yuqing, Dang, Qin, Liu, Long, Zhang, Jian, Luo, Peng, Ren, Jianzhuang, Han, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271859/
https://www.ncbi.nlm.nih.gov/pubmed/35833141
http://dx.doi.org/10.3389/fimmu.2022.910582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271859/
https://www.ncbi.nlm.nih.gov/pubmed/35833141
http://dx.doi.org/10.3389/fimmu.2022.910582

Ejemplares similares